Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation (FMT) for the treatment of recurrent C. difficile infections (rCDI) has opened a frontier of restorative therapies targeting the gut microbiome.  This study aims to explore the relationship between intestinal microbiota and Crohn’s disease (CD) phenotype and test whether changing the microbiota canimprove CD inflammation. THIS STUDY IS ENROLLING BY INVITATION ONLY - IU Investigators will recruit, consent, confirm eligibility criteria, and enroll patients from the clinic. Screening will be centered around the endoscopy schedule. Patients with CD who are scheduled for a clinical exam for any indication will be pre-screened in the electronic medical record. If potentially eligible, the research team will contact the clinical team about the stud and they will be connected to the study coordinator to schedule a screening visit.

The purpose of this study is to evaluate the technical and operational performance of Lovelace in comparison with the clinical standard-of-care CTG for antepartum fetal monitoring (i.e. NST), and to collect evidence of its safety. The main objective is to evaluate the safety and performance of Lovelace for antepartum monitoring in pregnant women at gestational ages of 32 weeks or greater, in comparison with the standard- of-care CardioTocoGraph (CTG).THIS STUDY IS ENROLLING BY INVITATION ONLY - This study is enrolling pregnant women of 18 years of age, or older, at the time of consent, with a singleton pregnancy, and with the gestational age of 32 weeks or above. Potential participants will be invited to participate by the study team.

INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to THIS STUDY IS ENROLLING BY INVITATION ONLY 

This phase I trial studies the side effects and best dose of trametinib and everolimus ing pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth.verolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas comparedb or everolimus alone.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632